
Sign up to save your podcasts
Or


The utility of prostate-specific antigen (PSA) screening for prostate cancer detection is impacted by detection of cancers with low risk of mortality. Editorialist Jeffrey J. Tosoian, MD, MPH, discusses a pragmatic approach to prostate cancer screening with JAMA Deputy Editor Mary L. (Nora) Disis, MD. Related Content:
By JAMA Network4.6
162162 ratings
The utility of prostate-specific antigen (PSA) screening for prostate cancer detection is impacted by detection of cancers with low risk of mortality. Editorialist Jeffrey J. Tosoian, MD, MPH, discusses a pragmatic approach to prostate cancer screening with JAMA Deputy Editor Mary L. (Nora) Disis, MD. Related Content:

38,503 Listeners

43,648 Listeners

27,024 Listeners

132 Listeners

319 Listeners

543 Listeners

708 Listeners

502 Listeners

6,441 Listeners

298 Listeners

266 Listeners

3,387 Listeners

21 Listeners

15 Listeners

7 Listeners

7 Listeners

19 Listeners

30 Listeners

90 Listeners

521 Listeners

367 Listeners

18 Listeners

376 Listeners